Search for: "NAFLD" - 10 articles found

Photo

MR Elastography

MRE plus Fib-4 prove highly accurate in liver fibrosis detection

Researchers have found that coupling image-based and serum-based biomarkers achieves a higher diagnostic accuracy in detecting stage 2 liver fibrosis or above, than using the techniques separately. They reached their conclusions after using magnetic resonance elastography (MRE) in tandem with the serum-based Fib-4 clinical prediction rule.

Photo

Infrared imaging

New imaging method to detect and monitor liver disease

It’s currently difficult to screen for certain liver diseases and to monitor these conditions once they’re discovered. A team led by investigators at Massachusetts General Hospital (MGH) and the Massachusetts Institute of Technology (MIT) recently developed a non-invasive imaging method that has promising clinical potential to accomplish both goals. The technique is described in a study…

Photo

Surprising discovery

Fatty liver disease can also affect lean people

Non-alcoholic fatty liver disease (NAFLD) is mostly diagnosed in overweight and obese people. However, severe forms of NAFLD can also be detected in rare genetic diseases such as lipodystrophy or in patients with HIV, putting them at a high risk for developing liver failure, diabetes and cardiovascular diseases. Norbert Stefan and colleagues have now detected a yet unknown cause of NAFLD in lean…

Photo

Non-alcoholic fatty liver disease

3D model of human liver tissue for better NAFLD diagnosis

Non-alcoholic fatty liver disease (NAFLD) is becoming the most common chronic liver disorder in developed countries. Histological analysis of liver tissue is the only widely accepted test for diagnosing and distinguishing different stages of NAFLD. However, this technique provides only two-dimensional images of the liver tissue in low resolution and overlooks potentially important 3D structural…

Photo

LITMUS vs NAFLD

Towards better diagnosis and treatment of liver disease

A pioneering European research project designed to develop new diagnostic tests to assess patients with Non-Alcoholic Fatty Liver Disease (NAFLD) has expanded giving access to more patients. Liver Investigation: Testing Marker Utility in Steatohepatitis (LITMUS) funded by the European Innovative Medicines Initiative 2 Joint undertaking, brings together clinical scientists from international…

Photo

Subgroup detected

A new Diabetes classification?

The traditional classification of diabetes, mainly in type 1 and type 2 diabetes, has been challenged by studies from Scandinavia. In the current issue of The Lancet Diabetes & Endocrinology, researchers from DDZ together with colleagues from DZD and University of Lund published a cluster analysis of diabetes allowing for phenotyping into subgroups, which extended the findings by showing that…

Photo

NAFLD

Fatty liver disease: critical regulator discovered

Non-alcoholic fatty liver disease (NAFLD) is a condition where fat accumulates in the liver and has become the most common liver disease worldwide. While NAFLD shows few or no symptoms at initial stages, it is a potentially serious disease which can progress to an inflammatory state called steatohepatitis (NASH), which can lead to liver cirrhosis and cancer. Fatty liver disease can be managed by…

Photo

Side effects

Do common acid reflux medications promote chronic liver disease?

Approximately 10 percent of the general population take a proton pump inhibitor (PPI) drug to block stomach acid secretions and relieve symptoms of frequent heartburn, acid reflux and gastroesophageal reflux disease. That percentage can be as much as seven times higher for people with chronic liver disease. Researchers at University of California San Diego School of Medicine have discovered…